# First-in-human Study of OVM-200 as a Therapeutic Cancer Vaccine

> **NCT05104515** · PHASE1 · RECRUITING · sponsor: **Oxford Vacmedix UK Ltd.** · enrollment: 36 (estimated)

## Conditions studied

- Prostate Cancer
- Non Small Cell Lung Cancer
- Ovarian Cancer

## Interventions

- **BIOLOGICAL:** OVM-200

## Key facts

- **NCT ID:** NCT05104515
- **Lead sponsor:** Oxford Vacmedix UK Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-11-01
- **Primary completion:** 2025-11-30
- **Final completion:** 2026-01-31
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2025-02-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05104515

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05104515, "First-in-human Study of OVM-200 as a Therapeutic Cancer Vaccine". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05104515. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*